Antiretroviral adherence and development of drug resistance are the strongest predictors of genital HIV-1 shedding among women initiating treatment.

Persistent genital human immunodeficiency virus type 1 (HIV-1) shedding among women receiving antiretroviral therapy (ART) may present a transmission risk. We investigated the associations between genital HIV-1 suppression after ART initiation and adherence, resistance, pretreatment CD4 cell count, and hormonal contraceptive use. First-line ART was initiated in 102 women. Plasma and genital HIV-1 RNA levels were measured at months 0, 3, and 6. Adherence was a strong and consistent predictor of genital HIV-1 suppression (P < .001), whereas genotypic resistance was associated with higher vaginal HIV-1 RNA level at month 6 (P = .04). These results emphasize the importance of adherence to optimize the potential benefits of ART for reducing HIV-1 transmission risk.

[1]  Connie Celum,et al.  Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis , 2010, The Lancet.

[2]  J. Overbaugh,et al.  Lower Risk of Resistance After Short-Course HAART Compared With Zidovudine/Single-Dose Nevirapine Used for Prevention of HIV-1 Mother-to-Child Transmission , 2009, Journal of acquired immune deficiency syndromes.

[3]  Matthias Egger,et al.  Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis , 2009, AIDS.

[4]  A. Fauci,et al.  Universal voluntary testing and treatment for prevention of HIV transmission. , 2009, JAMA.

[5]  J. Hogan,et al.  Antiretroviral drug concentrations and HIV RNA in the genital tract of HIV-infected women receiving long-term highly active antiretroviral therapy. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  J. Overbaugh,et al.  Initiation of antiretroviral therapy leads to a rapid decline in cervical and vaginal HIV-1 shedding , 2007, AIDS.

[7]  J. Ndinya-Achola.  Graham SM, Holte SE, Peshu NM, Richardson BA, Panteleeff DD, Jaoko WG, Ndinya-Achola JO, Mandaliya KN, Overbaugh JM, McClelland RS.Initiation of antiretroviral therapy leads to a rapid decline in cervical and vaginal HIV-1 shedding.AIDS. 2007 Feb 19;21(4) , 2007 .

[8]  A. Caliendo,et al.  Differences in HIV-1 pol Sequences From Female Genital Tract and Blood During Antiretroviral Therapy , 2003, Journal of acquired immune deficiency syndromes.

[9]  C. Rousseau,et al.  Validation of Performance of the Gen-Probe Human Immunodeficiency Virus Type 1 Viral Load Assay with Genital Swabs and Breast Milk Samples , 2002, Journal of Clinical Microbiology.

[10]  Mardge H. Cohen,et al.  Determinants of HIV-1 shedding in the genital tract of women , 2001, The Lancet.

[11]  H. Sheppard,et al.  Comparison of Techniques for HIV‐1 RNA Detection and Quantitation in Cervicovaginal Secretions , 2001, Journal of acquired immune deficiency syndromes.

[12]  A. Caliendo,et al.  Effect of highly active antiretroviral therapy on cervicovaginal HIV-1 RNA , 2000, AIDS.

[13]  B. Chohan,et al.  Hormonal contraception, vitamin A deficiency, and other risk factors for shedding of HIV-1 infected cells from the cervix and vagina , 1997, The Lancet.